PO10-TU-39 Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
2009 ◽
Vol 285
◽
pp. S206
◽
2009 ◽
Vol 285
◽
pp. S114
◽
2009 ◽
Vol 2009
◽
pp. 99-103
2008 ◽
Vol 7
(9)
◽
pp. 796-804
◽
1999 ◽
Vol 67
(4)
◽
pp. 451-456
◽
2012 ◽
Vol 11
(2)
◽
pp. 131-139
◽